Contemporary management of Lung cancer: Hope to Reality

Lung cancer is the most frequently diagnosed cancer worldwide and a major health problem in both developed and developing countries. The fourth most common malignancy in our country, lung cancer is also the leading cause of cancer mortality among Indian males and is expected to remain a major health problem for the next 30-40 years, even if there is a reduction in incidence as a result of smoking cessation interventions.

The treatment landscape of lung cancer has undergone a paradigm shift in the past decade from a conventional approach to a more personalised strategy, owing to the development of effective screening methods, advancements in imaging modalities, nuanced surgical techniques, technological innovations in radiation delivery techniques and sophisticated molecular pathology practices. The biggest breakthroughs however, have been in the evolution of indications for the use of immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and therapies targeting specific genetic alterations. Indeed, these agents have revolutionized the management of lung cancer.

Through this year's evidence-based medicine (EBM) meeting, participants will have an opportunity to remain up to date in the state-of-the-art scientific advances and technologies.This meeting aims to highlight the recent evidence in the management of lung malignancy encompassing the latest progress in surgery, radiation oncology, radiology, pathology, molecular pathology, pulmonary medicine and medical oncology

As has been the tradition in the past EBMs, through this meeting, physicians involved in the management of lung cancer would be able to determine how the latest scientific advances will affect their day-to-day clinical practice and understand which advances represent new standards of care, thereby bridging competency gaps across the various specialties.

Key highlights of the meeting:

• Evidence-based, practical and tailored approach to Lung cancer management
• Comprehensive review from diagnosis to rehabilitation strategies
• Debates and panel discussion on key controversial topics in Lung cancer
• Review of the evidence and its generalisability by reputed experts
• International and national faculty
• Molecular pathology pre-conference workshop with special focus on advanced
  molecular diagnosis of Lung cancer

Organizing Chairman: Dr. Jai Prakash Agarwal
Organizing Secretary: Dr. Naveen Mummudi

Musculoskeletal Oncology : Current Practices and Bridging the Gaps! 

This three-day meeting is planned to provide an overview of common bone and soft tissue tumors to provide evidence for various unresolved and evolving gaps in orthopedic oncology care. Renowned International and National faculty members will cover these topics in a focused and succinct manner. The target audience for the meeting is surgical oncologists, radiation and medical oncologists, interventional and diagnostic radiologists, pathologists, orthopedic surgeons, rehabilitation specialists, researchers, and residents training in any of the specialties.

We have planned dedicated disease-specific multidisciplinary sessions along with pre-conference workshops in the fields of Intervention Radiology and surgical oncology. In addition, we will also discuss established and evolving evidence related to Fibromatoses, other rare and evolving histologic subtypes, ablative procedures, particle therapy, and newer technical advances utilized in Musculoskeletal Oncology. The collated evidence will be published in the form of an “EBM book.”

We urge you to grab this opportunity to get updated on the available evidence and interact with the stalwarts of Musculoskeletal oncology.
We look forward to welcoming you to this annual event.

Key highlights of the meeting:

• Diagnosis And Staging
• Osteogenic Sarcoma 
• Ewing Sarcoma 
• Soft Tissue Sarcoma
• Sarcoma Genetics And Surveillance
• Minimally Invasive Treatments
• Technological Advancement
• Session On Emerging Evidence

Organizing Chairman- Dr. Ashish Gulia
Organizing Secretary- Dr. Amit Janu